Investors

Investors

We aim to build an ecosystem around gene therapy through strategic venture-tech collaborations, backed by our robust fundraising network, capabilities to support quick-scaling innovations and highly experienced leadership team.
  • CITIC Medical Fund, an equity investment management platform committed to building a comprehensive pharmaceutical industry fund with in-depth industry integration capabilities. The CITIC Medical team comprises industry professionals with many years of experience in multinational pharmaceutical companies, as well as financial experts who have in-depth experience in the financial field. CITIC Medical Fund has invested in over 10 leading companies, including JYSS Bio, Simcere Pharmaceutical, Hengsheng Medical, Raynovent Biotech, and more.
  • Tigermed, a pioneer clinical Contract Research Organization (CRO) in China, dedicated to providing new drug research and clinical development services to global and Chinese pharmaceutical and biotechnology companies. Since its inception in 2004, Tigermed has embraced partnerships to accelerate product development and generate the clinical evidence that its clients require. Since 2014, Tigermed has invested in more than 60 funds and nearly 90 direct investment projects, involving more than 400 investment projects after penetration. Tigermed has a wide range of customers and partners, including I-Mab Biopharma and Antengene Corp.
  • HLC (Highlight Capital), an investment company with a mission to promote technological innovations based on scientific and industrial insights. They focus on enabling high-growth sectors such as healthcare and biotech. HLC currently manages over $2 billion and has invested in over 90 leading companies, with more than 20 of them listed on the Shanghai Stock Exchange, Hong Kong Stock Exchange, and Nasdaq, including Mindray, Wuxi Apptec, Tigermed, Pharmaron, United Imaging, Brightgene, Genetron, Zentalis, Singular, Nayuki and more.

  • Anlongmed Fund, an investment fund established in 2015 that invests in early and growth-stage companies in the life sciences industry, including pharmaceuticals, medical devices, and medical services. The management team has vast experience in scientific research, multinational companies, entrepreneurship, and investment. Anlong Fund has invested in over 40 companies, of which five are listed or entering the IPO process. I-Mab and Connect Biopharma are listed on Nasdaq in the U.S., and Hanyu Medical, GKHT Medical, and Inmagene are soon to list.

  • Oceanpine Capital, is an institutional growth equity investment company formed by seasoned entrepreneurs and sophisticated investors with 20 years of in-depth industry operational and business building experiences in both China and the US. With a perspective of achieving successful growth over the long term, Oceanpine partners visionary entrepreneurs to build world-class companies together on a lasting impact.

  • TigerYeah Capital, is a venture capital firm that focuses on investments in the healthcare industry. The firm seeks to make investments in the medical and health field precisely, aiding companies developing medical equipment and providing CRO and medical services. The management team has profound investment experience across the healthcare industry and invested more than $1 billion in more than 60 medical device companies.

  • Yuanlai Capital, is headquartered in Shanghai and was co-founded by sophisticated investors with in-depth industry operational and business-building experiences. The firm seeks to make investments in the healthcare field. By partnering with Tigermed, the leading research company in China, Yuanlai Capital invested more than $100 million in seed funding for life science start-ups.